Harshitha Pidikiti

Harshitha Pidikiti

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2025 in Brain Sciences
Verified
Journal Article
Open access
PDF file
ALAmanda Labuza
Amanda Labuza
HPHarshitha Pidikiti
Harshitha Pidikiti
MAMelissa J. Alldred
Melissa J. Alldred
KIKyrillos W. Ibrahim
Kyrillos W. Ibrahim
KPKatherine Peng
Katherine Peng
Stephen GinsbergStephen Ginsberg
Stephen Ginsberg
Background: Apolipoprotein E (APOE) is the strongest genetic risk determinant for late-onset Alzheimer’s disease (AD). The APOE3 allele is risk-neutral, the APOE4 allele increases the risk of developing AD, and the APOE2 allele is neuroprotective. Methods: We utilized RNA sequencing of hemi-brains from a mouse model homozygous for each of these humanized APOE alleles to study gene expression profiles between mice aged 12 months of age (MO) and 18 MO, independent of β-amyloid and tau pathology. Results: More than half of the differentially expressed genes (DEGs) within each genotype were shared with at least one other APOE allele, including 1610 DEGs that were shared across the three genotypes. These DEGs represent changes driven by aging rather than APOE genotype. Aging induced DEGs and biological pathways involving metabolism, synaptic function, and protein synthesis, among others. Alterations in these pathways were also identified by DEGs unique to APOE4, suggesting that the APOE4 allele drives the aging phenotype. In contrast, fewer pathways were identified from DEGs unique to APOE2 or APOE3. Conclusions: Transcriptomic results suggest that the most significant impact on brain-level expression changes in humanized APOE mice is aging and that APOE4 exacerbates this process. These in vivo findings within an established model system are consistent with brain aging being the greatest risk factor for AD and suggest that APOE4 expression promotes an aging phenotype in the brain that interacts with, and contributes to, aging-driven AD risk. Results reinforce the impact age and APOE allele contribute to AD and age-related neurodegeneration, and foster greater mechanistic understanding as well as inform therapeutic intervention.

5 August 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
MAMelissa J. Alldred
Melissa J. Alldred
HPHarshitha Pidikiti
Harshitha Pidikiti
KIKyrillos W. Ibrahim
Kyrillos W. Ibrahim
SLSang Han Lee
Sang Han Lee
AHAdriana Heguy
Adriana Heguy
Stephen GinsbergStephen Ginsberg
Stephen Ginsberg
Down syndrome (DS), stemming from the triplication of human chromosome 21, results in intellectual disability, with early mid-life onset of Alzheimer’s disease (AD) pathology. Early interventions to reduce cognitive impairments and neuropathology are lacking. One modality, maternal choline supplementation (MCS), has shown beneficial effects on behavior and gene expression in neurodevelopmental and neurodegenerative disorders, including trisomic mice. Loss of basal forebrain cholinergic neurons (BFCNs) and other DS/AD relevant hallmarks were observed in a well-established trisomic model (Ts65Dn, Ts). MCS attenuates these endophenotypes with beneficial behavioral effects in trisomic offspring. We postulate MCS ameliorates dysregulated cellular mechanisms within vulnerable BFCNs, with attenuation driven by novel gene expression. Here, choline acetyltransferase immunohistochemical labeling identified BFCNs in the medial septal/ventral diagonal band nuclei of the basal forebrain in Ts and normal disomic (2N) offspring at ~11 months of age from dams exposed to MCS or normal choline during the perinatal period. BFCNs (~500 per mouse) were microisolated and processed for RNA-sequencing. Bioinformatic assessment elucidated differentially expressed genes (DEGs) and pathway alterations in the context of genotype (Ts, 2N) and maternal diet (MCS, normal choline). MCS attenuated select dysregulated DEGs and relevant pathways in aged BFCNs. Trisomic MCS-responsive improvements included pathways such as cognitive impairment and nicotinamide adenine dinucleotide signaling, among others, indicative of increased behavioral and bioenergetic fitness. Although MCS does not eliminate the DS/AD phenotype, early choline delivery provides long-lasting benefits to aged trisomic BFCNs, indicating that MCS prolongs neuronal health in the context of DS/AD.

23 October 2026 in Brain Sciences
Verified
Journal Article
Open access
PDF file
YCYun-juan Chang
Yun-juan Chang
PSPhilip H. Stavrides
Philip H. Stavrides
HPHarshitha Pidikiti
Harshitha Pidikiti
KIKyrillos W. Ibrahim
Kyrillos W. Ibrahim
JLJu-hyun Lee
Ju-hyun Lee
Stephen GinsbergStephen Ginsberg
Stephen Ginsberg
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder where early molecular disruptions precede overt pathology and neuronal loss. To identify transcriptional events that bias neurons toward degeneration or resilience, we reanalyzed two single-nucleus RNA-sequencing datasets originally generated to investigate glial responses in an established AD murine model. Methods: Using a neuron-centric analytical framework, excitatory neuronal cells were selected for downstream bioinformatics involving unsupervised clustering, trajectory inference, and functional analyses. Results: This approach revealed neuronal heterogeneity and enabled reconstruction of inferred transcriptional trajectories in a discovery dataset. Three distinct neuronal states along an inferred continuum from stability to degeneration were identified: a homeostatic state, a transitional stress-adaptive state, and an AD-associated state. The transitional state was positioned near a trajectory bifurcation point, indicating divergence toward either partial resilience or an AD-like trajectory. Differential gene expression and pathway analyses revealed RNA-processing dysregulation in the transitional state, suggesting that early alterations in RNA metabolism may play a key role in biasing neurons toward pathological progression. The homeostatic and transitional neuronal states were independently validated, whereas the AD-associated state was not, potentially reflecting differences in brain-region sampling, sequencing strategies, and/or the transient nature of the disease-associated state. Conclusions: This study identified distinct neuronal transcriptional states and inferred trajectories associated with AD-related vulnerability, highlighting RNA-processing dysfunction as a candidate mechanistic contributor of neuronal fate divergence in AD progression. This work provides a foundation for future studies to define cell-type-specific RNA dysregulation in relevant animal models and human postmortem brain tissues to determine whether early RNA-metabolic imbalance and upstream signaling drivers can serve as mechanistic biomarkers or therapeutic intervention points in AD.